CG
PTCT icon

Cutler Group’s PTC Therapeutics PTCT Stock Holding History

Cutler Group’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,300
Closed -$1K – 4465
2018
Q3 		$1K Sell
2,300
-2,500
-52% -$103K ﹤0.01% 3841
2018
Q2 		$11K Sell
4,800
-500
-9% -$15.6K ﹤0.01% 2615
2018
Q1 		$22K Sell
5,300
-14,000
-73% -$355K ﹤0.01% 2216
2017
Q4 		$52K Sell
19,300
-419,200
-96% -$7.1M ﹤0.01% 1831
2017
Q3 		$574K Buy
438,500
+400,400
+1,051% +$7.84M 0.02% 592
2017
Q2 		$174K Sell
38,100
-90,500
-70% -$1.22M 0.01% 1397
2017
Q1 		$315K Buy
128,600
+73,400
+133% +$888K 0.01% 881
2016
Q4 		$120K Sell
55,200
-5,000
-8% -$52.5K ﹤0.01% 1748
2016
Q3 		$75K Buy
60,200
+39,100
+185% +$318K ﹤0.01% 2066
2016
Q2 		$89K Sell
21,100
-8,700
-29% -$63.8K ﹤0.01% 1792
2016
Q1 		$280K Sell
29,800
-33,900
-53% -$588K 0.02% 815
2015
Q4 		$538K Buy
+63,700
New +$1.87M 0.03% 578

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Cutler Group's PTCT Position: Q1 2019 in Review

Cutler Group sold out of PTC Therapeutics (PTCT) in Q1 2019, closing a stake of 274 shares — an estimated $9.2K sold.

Cutler Group first reported a position in PTCT in Q4 2015 and held it in 13 quarters. The position peaked at $1.28M in Q3 2017. 174 funds tracked by Wall St. Rank hold PTCT as of Q1 2019.

  • Cutler Group reported no remaining PTC Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Cutler Group sold 274 PTC Therapeutics shares in Q1 2019, an estimated $9.2K.
  • Cutler Group first reported a position in PTC Therapeutics in Q4 2015 and held it in 13 quarters.
  • Cutler Group's PTC Therapeutics position peaked at $1.28M in Q3 2017.
  • 174 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2019.

Based on Cutler Group's 13F filing for Q1 2019, filed 10 May 2019.